MedTrace Logo

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

NCT00382811 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2016-07-18

No results posted yet for this study

Summary

The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may result.

Conditions

Interventions

DRUG

phenoxodiol

400mg phenoxodiol three times daily in 28 day cycles.

DRUG

carboplatin

AUC=2 weekly in 28 day cycles

DRUG

placebo

every 8 hours daily in 28 day cycles

Sponsors & Collaborators

  • MEI Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Daniel P Gold, PhD · MEI Pharma, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-04-30
Completion
2011-04-30

Countries

  • United States
  • Australia
  • Belgium
  • Italy
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00382811 on ClinicalTrials.gov